Breaking News Instant updates and real-time market news.

NVDA

NVIDIA

$94.11

-0.05 (-0.05%)

, AMD

AMD

$8.83

0.06 (0.68%)

07:32
11/29/16
11/29
07:32
11/29/16
07:32

Jefferies takes stance on semis to neutral from bullish

Jefferies analyst Mark Lipacis is taking his stance on the Semiconductors space to neutral from bullish following the Q3 earnings season. The earnings reports revealed two yellow flags, Lipacis tells investors in a research note. One, the companies have benefited from an inventory restock since Q2 and are forecasted to outship manufactures thru the first half of 2017, the analyst contends. And two, semi days of inventory has declined, historically a leading indicator of SOX peaks, Lipacis contends. He feels a more neutral stance on the sector is warranted and prefers product cycle stories NVIDIA (NVDA), AMD (AMD), MACOM (MTSI) and Inphi (IPHI).

NVDA

NVIDIA

$94.11

-0.05 (-0.05%)

AMD

AMD

$8.83

0.06 (0.68%)

MTSI

MACOM

$49.00

0.64 (1.32%)

IPHI

Inphi

$46.68

-0.52 (-1.10%)

  • 29

    Nov

  • 05

    Dec

  • 07

    Dec

  • 14

    Dec

  • 15

    Dec

NVDA NVIDIA
$94.11

-0.05 (-0.05%)

11/23/16
SBSH
11/23/16
NO CHANGE
Target $100
SBSH
Buy
NVIDIA gaming growth being underappreciated, says Citi
Citi analyst Atif Malik views data center and auto as attractive markets for NVIDIA over the mid to long term, but says the Street continues to underestimate the sales and earnings contribution from core gaming. He expects NVIDIA over the long term to maintain 70%-plus unit share in the high end gaming market "on better performance and brand loyalty." Malik reiterates a Buy rating on the shares with a $100 price target.
11/22/16
MKMP
11/22/16
NO CHANGE
MKMP
Buy
MKM Partners raises NVIDIA, AMD price targets on inflecting semi opportunities
MKM Partners analyst Ian Ing raised his price target for NVIDIA (NVDA) to $106 from $87, saying that thematic attention is heating up as large suppliers are crowding into artificial intelligence as an investment theme with non-GPU solutions. While other suppliers may be able to come up with better performance-for-power in certain use cases, he believes NVIDIA GPUs still have user stickiness with developer incumbency and easy-to-use tools that will be difficult to overcome. The analyst also raised his price target for AMD (AMD) to $10.50 from $8 to reflect improved prospects for the company driven by new product pipeline. Although Ian expects AMD to be a relatively minor player, its shares are helped by continued A.I. headlines and NVIDIA, Intel (INTC), and Qualcomm (QCOM) turning increasingly vocal on the opportunity. He reiterates a Buy rating on NVIDIA and AMD shares.
11/14/16
11/14/16
UPGRADE
Target $100

Buy
NVIDIA upgraded to Buy at Needham
As previously reported, Needham analyst Rajvindra Gill upgraded NVIDIA to Buy from Hold, with a $100 price target, after the company's "significant" beat and raise quarter. The analyst says his view is based on long-term secular trends, namely the incorporation of ADAS applications in automotive market and where NVIDIA's Drive PX2 supplies Level 3-5 autonomy, the proliferation of machine learning, AI and graphics virtualization in the data center, and the emergence of virtual reality devices in PC and gaming markets driving higher graphics content.
11/14/16
ROTH
11/14/16
NO CHANGE
Target $95
ROTH
Buy
NVIDIA price target raised to $95 from $73 at Roth Capital
Roth Capital analyst Brian Alger raised his price target for NVIDIA to $95 from $73 after the company reported another "truly incredible" quarterly update. The analyst reiterates a Buy rating on the shares.
AMD AMD
$8.83

0.06 (0.68%)

10/21/16
ADAM
10/21/16
NO CHANGE
Target $9
ADAM
Buy
AMD weakness a buying opportunity, says Canaccord
Canaccord analyst Matthew Ramsay said AMD reported "solid" Q3 results and provided seasonally lower guidance, which was expected. The analyst said his buy thesis remains intact and the selloff in the after hours was unwarranted. Ramsay said the weakness in the shares is a buying opportunity with the risk/reward tilted toward the upside upon entering an important year for the company's turnaround. Ramsay reiterated his Buy rating and $8.50 price target on AMD shares.
10/21/16
BERN
10/21/16
NO CHANGE
BERN
AMD outlook 'sounds promising,' says Bernstein
Bernstein analyst Stacy Rasgon says that AMD's Q3 results were "strong," and the analyst says that the comments and evidence presented by the company about its design wins and engagements "sound promising." Rasgon says she's weary about AMD, given its past missteps, but the analyst admits that she "just might be warming up to the story." Rasgon raised her price target on the shares to $7.50 from $6 but keeps a Market Perform rating on the stock.
10/21/16
SBSH
10/21/16
NO CHANGE
Target $3.5
SBSH
Sell
AMD continues to lose money, says Citi
Citi analyst Christopher Danely keeps a Sell rating on AMD following the company's Q3 results. AMD continues to lose money despite improving fundamentals with estimated net debt of $353.3M, Danely tells investors in a research note. He raised his price target for the shares to $3.50 from $2.50.
MTSI MACOM
$49.00

0.64 (1.32%)

09/20/16
GSCO
09/20/16
DOWNGRADE
Target $41
GSCO
Neutral
MACOM downgraded to Neutral from Buy at Goldman
Goldman analyst Mark Delaney downgraded MACOM to Neutral citing valuation and maintained its $41 price target.
11/22/16
ADAM
11/22/16
DOWNGRADE
Target $8
ADAM
Hold
Applied Micro Circuits downgraded to Hold from Buy at Canaccord
Canaccord analyst Matthew Ramsay downgraded Applied Micro Circuits (AMCC) to Hold from Buy following the announcement it would be acquired by MACOM (MTSI) for $8.36 per share in cash and stock.
11/21/16
ROTH
11/21/16
DOWNGRADE
Target $8
ROTH
Neutral
Applied Micro Circuits downgraded to Neutral from Buy at Roth Capital
Roth Capital analyst Suji Desilva downgraded Applied Micro Circuits (AMCC) to Neutral from Buy, with an $8 price target, on the announcement of its planned stock plus cash acquisition by MACOM Technologies (MTSI). The analyst expects the acquisition to face limited anti-trust or regulatory issues given the lack of direct product market overlap, and believes MACOM will focus on the connectivity business and divest the Applied Micro Circuits compute business within approximately three months' timeframe.
10/31/16
NEED
10/31/16
NO CHANGE
NEED
Needham remains bullish on Optical Sector
Needham analyst Alex Henderson believes the "Optical Super Cycle" is going full steam ahead and strongly reiterates his bullish view on the Optical Sector. The analyst believes that most of the angst over the last week around the optical sector is a non-issue. Henderson is an aggressive buyer on weakness of Lumentum (LITE), NeoPhotonics (NPTN), Oclaro (OCLR), and Inphi (IPHI). Finisar (FNSR), Fabrinet (FN), II-VI (IIVI), GigPeak (GIG) and MACOM (MTSI) are also strong recommendations, he added. Further, Henderson believes Acacia Communications (ACIA) has "way overcorrected," and thinks it can rebound on a stronger Q4 outlook and upside to 2017 numbers.
IPHI Inphi
$46.68

-0.52 (-1.10%)

11/02/16
ROTH
11/02/16
NO CHANGE
Target $50
ROTH
Buy
Inphi price target raised to $50 from $44 at Roth Capital
Roth Capital analyst Brian Alger raised his price target for Inphi to $50 from $44 after the company delivered a "strong" report. Now heading into 2017, Inphi looks to benefit from ColorZ, continued strong long-haul and metro demand in China, and the just announced acquisition of ClariPhy, Alger noted. The analyst reiterates a Buy rating on the shares.
10/14/16
COWN
10/14/16
INITIATION
Target $39
COWN
Market Perform
Inphi initiated with a Market Perform at Cowen
Cowen analyst Wayne Loeb initiated Inphi with a Market Perform rating and $39 price target. The analyst said PAM4 adoption in the data center and proprietary DCI adoption is coming, but somewhat later than expected.
09/07/16
NORL
09/07/16
DOWNGRADE
NORL
Market Perform
Inphi downgraded to Market Perform from Outperform at Northland

TODAY'S FREE FLY STORIES

XOM

Exxon Mobil

$87.04

-0.2 (-0.23%)

21:12
12/04/16
12/04
21:12
12/04/16
21:12
Periodicals
Trump widens Secretary of State search, will interview Exxon Mobil CEO, WSJ says »

President-elect Donald…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NVS

Novartis

$68.17

0.42 (0.62%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

21:08
12/04/16
12/04
21:08
12/04/16
21:08
Periodicals
Novartis CEO downplays possibility of Actelion bid, Reuters says »

Asked whether Novartis…

NVS

Novartis

$68.17

0.42 (0.62%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

PCRFY

Panasonic

$10.58

0.19 (1.83%)

21:05
12/04/16
12/04
21:05
12/04/16
21:05
Periodicals
Panasonic eyes European headlight maker ZKW, Nikkei says »

Panasonic plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$109.90

0.41 (0.37%)

21:03
12/04/16
12/04
21:03
12/04/16
21:03
Hot Stocks
Apple comments on U.S. autonomous cars policy, says 'excited' about potential »

The U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

ETP

Energy Transfer Partners

$34.38

1.16 (3.49%)

20:46
12/04/16
12/04
20:46
12/04/16
20:46
Hot Stocks
Army says will not grant easement for Dakota Access Pipeline »

The Department of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INCY

Incyte

$102.02

2.09 (2.09%)

, PFE

Pfizer

$31.63

0.17 (0.54%)

20:25
12/04/16
12/04
20:25
12/04/16
20:25
Conference/Events
Canaccord biotech analyst to hold a dinner meeting »

In conjunction with the…

INCY

Incyte

$102.02

2.09 (2.09%)

PFE

Pfizer

$31.63

0.17 (0.54%)

LLY

Eli Lilly

$67.71

1.74 (2.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

  • 15

    Dec

AGIO

Agios Pharmaceuticals

$56.97

-1.09 (-1.88%)

20:11
12/04/16
12/04
20:11
12/04/16
20:11
Hot Stocks
Agios Pharmaceuticals reports data on AG-348, AG-519 »

Agios Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:59
12/04/16
12/04
19:59
12/04/16
19:59
Hot Stocks
Karyopharm reports updated Phase 2b STORM data »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ABBV

AbbVie

$59.43

0.27 (0.46%)

19:56
12/04/16
12/04
19:56
12/04/16
19:56
Hot Stocks
AbbVie reports data from two IMBRUVICA combination studies »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ABBV

AbbVie

$59.43

0.27 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

BPMC

Blueprint Medicines

$27.01

-0.99 (-3.54%)

19:50
12/04/16
12/04
19:50
12/04/16
19:50
Hot Stocks
Blueprint Medicines reports Phase 1 BLU-285 data »

Blueprint Medicines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INCY

Incyte

$102.02

2.09 (2.09%)

19:45
12/04/16
12/04
19:45
12/04/16
19:45
Hot Stocks
Incyte reports pooled analysis of five-year Jakafi data »

Incyte announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

GPRO

GoPro

$9.70

-0.12 (-1.22%)

19:42
12/04/16
12/04
19:42
12/04/16
19:42
Hot Stocks
GoPro releases $299 'Karma Grip' camera stabilizer »

GoPro announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 12

    Dec

KPTI

Karyopharm

$9.28

0.25 (2.77%)

19:37
12/04/16
12/04
19:37
12/04/16
19:37
Hot Stocks
Karyopharm reports data from Phase 2 SAIL study »

Karyopharm Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:32
12/04/16
12/04
19:32
12/04/16
19:32
Hot Stocks
Acetylon reports preclinical ACY-957 data »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

GBT

Global Blood Therapeutics

$19.10

-0.1 (-0.52%)

19:30
12/04/16
12/04
19:30
12/04/16
19:30
Hot Stocks
Global Blood Therapeutics reports Phase 1/2 GBT440 data »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 05

    Dec

  • 14

    Dec

  • 15

    Dec

  • 19

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

19:27
12/04/16
12/04
19:27
12/04/16
19:27
Hot Stocks
Acetylon reports initial Phase 1a/b data for citarinostat in myeloma »

Acetylon Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

XLRN

Acceleron

$36.29

1.25 (3.57%)

, CELG

Celgene

$117.63

-1.24 (-1.04%)

19:23
12/04/16
12/04
19:23
12/04/16
19:23
Hot Stocks
Acceleron, Celgene report updated data from Phase 2 luspatercept studies »

Acceleron Pharma (XLRN)…

XLRN

Acceleron

$36.29

1.25 (3.57%)

CELG

Celgene

$117.63

-1.24 (-1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 06

    Dec

ALNY

Alnylam

$41.57

-0.01 (-0.02%)

19:05
12/04/16
12/04
19:05
12/04/16
19:05
Hot Stocks
Alnylam reports Phase 2 data on fitusiran in hemophilia »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$122.96

0.95 (0.78%)

19:01
12/04/16
12/04
19:01
12/04/16
19:01
Hot Stocks
Alexion reports data from Phase 1/2 ALXN1210 study »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 14

    Dec

LYV

Live Nation

$27.07

-0.44 (-1.60%)

18:58
12/04/16
12/04
18:58
12/04/16
18:58
Hot Stocks
Live Nation acquires 51% stake in Australia's Secret Sounds Group »

Live Nation Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVS

Novartis

$68.17

0.42 (0.62%)

18:45
12/04/16
12/04
18:45
12/04/16
18:45
Hot Stocks
Novartis reports Phase 2 data on CTL019 in leukemia »

Novartis announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

ABBV

AbbVie

$59.43

0.27 (0.46%)

, JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

18:29
12/04/16
12/04
18:29
12/04/16
18:29
Hot Stocks
AbbVie reports five-year IMBRUVICA data, updated RESONATE-2 data »

AbbVie (ABBV) announced…

ABBV

AbbVie

$59.43

0.27 (0.46%)

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 06

    Dec

CELG

Celgene

$117.63

-1.24 (-1.04%)

18:17
12/04/16
12/04
18:17
12/04/16
18:17
Hot Stocks
Celgene, Dana-Farber, U of Arkansas form Myeloma Genome Project »

Celgene, Dana-Farber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

  • 06

    Dec

ARQL

ArQule

$1.37

-0.01 (-0.72%)

18:12
12/04/16
12/04
18:12
12/04/16
18:12
Hot Stocks
ArQule reports data presentation on ARQ 092 in sickle cell disease »

ArQule announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$98.50

-0.44 (-0.44%)

, TWX

Time Warner

$93.80

-0.34 (-0.36%)

18:08
12/04/16
12/04
18:08
12/04/16
18:08
Hot Stocks
Box Office Battle: 'Moana,' 'Fantastic Beasts' win post-Thanksgiving weekend »

Disney's (DIS)…

DIS

Disney

$98.50

-0.44 (-0.44%)

TWX

Time Warner

$93.80

-0.34 (-0.36%)

VIA

Viacom

$40.35

-1 (-2.42%)

VIAB

Viacom

$36.52

-0.74 (-1.99%)

SNE

Sony

$28.06

-0.16 (-0.57%)

FOX

21st Century Fox

$27.37

-0.71 (-2.53%)

FOXA

21st Century Fox

$27.40

-0.8 (-2.84%)

LGF

Lionsgate

$22.72

0.02 (0.09%)

CMCSA

Comcast

$68.78

-1.08 (-1.55%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.